Hematopoetik ve Lenfoid Maligniteler
Synopsis
This study examines the classification updated by the World Health Organization in 2016 and the core characteristics of hematopoietic and lymphoid tissue malignancies. These diseases are mainly categorized into three groups: myeloid, lymphoid, and histiocytic/dendritic neoplasms. Myeloproliferative neoplasms (Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis, Chronic Myeloid Leukemia) are characterized by increased cellular proliferation and genetic mutations such as JAK2, BCR-ABL1, and CALR, carrying risks of thrombosis, hemorrhage, or transformation into acute leukemia. Myelodysplastic syndromes represent a heterogeneous group manifesting with cytopenias, dysplasia, and ineffective hematopoiesis. Acute leukemias exhibit a rapid clinical course, presenting with over 20% blast cells in the bone marrow and profound cytopenias. Among mature lymphoid neoplasms, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma feature indolent or aggressive behaviors, whereas plasma cell neoplasms primarily include Plasma Cell Myeloma, Waldenström Macroglobulinemia, and asymptomatic Monoclonal Gammopathy of Undetermined Significance (MGUS). Morphology, immunophenotyping, molecular-genetic analyses, chemotherapy, targeted therapies, and immunomodulatory agents play critical roles in diagnosis and clinical management.
References
Türk Hematoloji Derneği Myelodisplastik Sendrom Tanı ve Tedavi Kılavuzu, Sürüm 1.4 – Eylül 2020.
Kronik Myeloid Lösemi ve Kronik Myeloproliferatif Neoplaziler Tanı ve Tedavi Kılavuzu Sürüm 1.03 - Ekim 2016.
Türk Hematoloji Derneği Multipl Myelom Tanı ve Tedavi Sürüm 1.03 - Mart 2020.
Eman B. Talal Q. Current Diagnostic Methods for Hematological Malignancies: A Mini-Review, Pharmacophore, 2020 11(3), 63-68.
Yun et al. Waldenström Macroglobülinemia: Review of Pathogenesis and ManagementClin Lymphoma Myeloma Leuk. 2017 May; 17(5): 252–262.
Xavier T., Edouard C, Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment Am J Hematol. 2017 Dec; 92(12): 1382–1390.
Jan A. B., Treatment of Chronic Lymphocytic Leukemia, N Engl J Med 2020;383:460-73.
Steven H. S., Elias C., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood. 2016;127(20):2375-2390.
Daniel A. A., Attilio O., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 2016;127(20):2391-2405,
Neha K, Sigurdur Y. Kristinsson, Ola L. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011 May 26; 117(21): 5573–5581.